Chemoprevention of breast cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 3, 2008, Pages 443-452

  Castrellon, Aurelio B ^a   Glück, Stefan ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Aromatase inhibitor; Breast cancer; Chemoprevention; Luteinizing hormone releasing hormone agonists; Phytoestrogen; Raloxifene; Statin; Tamoxifen

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; CAROTENOID; CYCLOOXYGENASE 2 INHIBITOR; DESLORELIN; ESTRADIOL; ESTROGEN; EXEMESTANE; FENRETINIDE; GENISTEIN; GONADORELIN AGONIST; GOSERELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; LAPATINIB; LETROZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTOESTROGEN; PLACEBO; PRAVASTATIN; RALOXIFENE; RETINOID; RETINOL DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; TAMOXIFEN; TESTOSTERONE; TRASTUZUMAB; UNINDEXED DRUG;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTERY EMBOLISM; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FRACTURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYSTERECTOMY; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; MASTECTOMY; MONOTHERAPY; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; OVARIECTOMY; OVERALL SURVIVAL; POSTMENOPAUSE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SALPINGOOOPHORECTOMY; SKIN TOXICITY; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CAROTENOIDS; CHEMOPREVENTION; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PHYTOESTROGENS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 45249117435     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.3.443     Document Type: Review

References (70)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
2. Jemal A, Siegel R. Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
3. Jemal A, Clegg LX, Ward E et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101, 3-27 (2004).
4. Weir HK, Thun MJ, Hankey BF et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J. Natl Cancer Inst. 95, 1276-1299 (2003).
5. Harlan LC, Abrams J, Warren JL et al. Adjuvant therapy for breast cancer: practice patterns of community physicians. J. Clin. Oncol. 20, 1809-1817 (2002).
6. Kelloff GJ, Hawk ET, Crowell JA et al. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology 10, 1471-1488 (1996).
7. Beatson GT. On the treatment of inoperable cases of carcinoma of the mama: suggestion for a new method of treatment with illustrative cases. Lancet 2, 104-107 (1896).
8. Feinleib M. Breast cancer and artificial menopause: a cohort study. J. Natl Cancer Inst. 41, 315-329 (1968).
9. Lupulescu AP. Hormones, vitamins and growth factors in cancer treatment and prevention. Cancer 78(11), 2264-2280 (1996).
10. Dickson R, Lippman ME. Growth factors in breast cancer. Endocr. Rev. 16, 559 (1995).
11. Janis K, Hoeltke J, Nazareth M et al. Estrogen decreases expression of chemokine receptors, and suppresses chemokine bioactivity in murine monocytes. Am. J. Reprod. Immunol. 51(1), 22-31 (2004).
12. Jiang X, Ellison SJ, Alarid ET, Shapiro DJ. Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells. Oncogene 26(28), 4106-4114 (2007).
13. Harlow BL, Signorello LB. Factors associated with early menopause. Maturitas 35, 3-9 (2000).
14. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 25, 127-205 (1984).
15. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90(18), 1371-1388 (1998).
16. Fisher B, Redmond C, Brown A et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J. Clin. Oncol. 4, 459-471 (1986).
17. Fisher B, Constantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N. Engl. J. Med. 320, 479-484 (1989).
18. Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst. 81, 1879-1886 (1989).
19. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 97, 1652-1662 (2005).
20. Powles T, Eeles R, Ashley SE, Easton D, Chang J, Dowsett L. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 352, 98-101 (1998).
21. Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352, 93-97 (1998).
22. Cuzick J, Forbes J, Edwards R et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet 360, 817-824 (2002).
23. Vogel VG. Raloxifene: a second-generation selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal women. Women Health 3, 139-153 (2007).
24. Jordan VC, Morrow M. Tamoxifen, raloxifen and the prevention of breast cancer. Endocr. Rev. 20, 253-278 (1999).
25. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 10(8), 905-912 (1996).
26. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifiene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281, 2189-2197 (1999).
27. Martino S, Cauley JA, Barrett-Connor E et al. Continuing outcomes relevant to evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 96, 1751-1761 (2004).
28. Barrett-Connor E, Mosca L, Collins P et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355, 125-137 (2006).
29. Pines A, Levo Y. Why is the RUTH trial so important? Maturitas 56(2), 111-112 (2007).
30. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361, 296-300 (2003).
31. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451-1467 (1998).
32. Vogel VG, Costantino, JP, Wickerham DL et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study Of Tamoxifen And Raloxifene (STAR) P-2 trial. JAMA 295, 2727-2741 (2006).
33. Lonning PE. Pharmacology of new aromatase inhibitors. Breast 5, 202-208 (1996).
34. Evans CT, Ledesma DB, Schulz TZ et al. Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P-450 mRNA. Proc. Natl Acad. Sci. USA 83, 6387-6391 (1986).
35. Geisler J, King N, Anker G et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin. Cancer Res. 4, 2089-2093 (1998).
36. Altundag K, Ibrahim NK. Aromatase inhibitors in breast cancer: an overview. Oncologist 11(6), 553-562 (2006).
37. Paridaens R, Therasse P, Dirix L et al. First line hormonal treatment (HT)for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - a randomized Phase III trial of the EORTC Breast Group. Proc. Am. Soc. Clin. Oncol. 23, 6 (2004).
38. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 21, 2101-2109 (2003).
39. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J. Clin. Oncol. 18, 3758-3767 (2000).
40. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98, 1802-1810 (2003).
41. Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum. Reprod. 9(7), 1364-1379 (1994).
42. Schally AV, Arimura A, Kastin AJ et al. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 173, 1036-1038 (1971).
43. Sharoni Y, Bosin E, Miinster A, Levy J, Schally AV. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc. Natl Acad. Sci. USA 86, 1648-1651 (1989).
44. Spicer DV, Pike MC, Pike A, Rude R, Shoupe D, Richardson J. Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer. Contraception 47, 427-444 (1993).
45. Simeone AM, Tari AM. How retinoids regulate breast cancer cell proliferation and apoptosis. Cell. Mol. Life Sci. 61, 1475-1484 (2004).
46. Lee JS, Newman RA, Lippman SM et al. Phase I evaluation of all-transretinoic acid in adults with solid tumors. J. Clin. Oncol. 11, 959-966 (1993).
47. Veronesi U, De Palo G, Marubini E et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl Cancer Inst. 91, 1847-1856 (1999).
48. Veronesi U, Mariani L, Decensi A et al. Fifteen-year results of a randomized Phase III trial of fenretinide to prevent second breast cancer. Ann. Oncol. 17(7), 1065-1071 (2006).
49. Zhang S, Hunter DJ, Forman MF et al. Dietary carotenoids and vitamins A, C and E and risk of breast cancer. J. Natl Cancer Inst. 91(6), 547-556 (1999).
50. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl Cancer Inst. 90, 1529-1536 (1998).
51. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase-2 gene expression in human breast cancer. Int. J. Oncol. 10, 503-507 (1997).
52. Hawk ET, Viner JL, Asad Umar A et al. Development of COX inhibitors in cancer prevention and therapy. Am. J. Cancer 26, S48-S57 (2003).
53. Cook NR, Lee IM, Gaziano JM et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294(1), 47-55 (2005).
54. Marshall SF, Bernstein L, Anton-Culver H et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J. Natl Cancer Inst. 97(11), 805-812 (2005).
55. Adlercreutz CH, Goldin BR, Gorbach SL et al. Soybean phytoestrogen intake and cancer risk. J. Nutr. 125, S757-S770 (1995).
56. Peterson G, Barnes S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem. Biophys. Res. Commun. 179, 661-667 (1991).
57. Sarkar FH, Li Y. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev. 21(3-4), 265-280 (2002).
58. Barnes S. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res. Treat. 46, 169-179 (1997).
59. Peeters PH, Keinan-Boker L, van der Schouw YT, Grobbee DE. Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. Breast Cancer Res. Treat. 77(2), 171-183 (2003).
60. Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 61, 5045-5050 (2001).
61. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16(4), 508-519 (2002).
62. Friis S, Poulsen AH, Johnsen SP et al. Cancer risk among statin users: a population-based cohort study. Int. J. Cancer 114, 643-647 (2005).
63. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin. Cancer Res. 9, 10-19 (2003).
64. Kochhar R, Khurana V, Bejjanki H et al. Statins reduce breast cancer risk: a case control study in U.S. female veterans. J. Clin. Oncol. 23(Suppl. 7), (2005) (Abstract 514).
65. Bonovas S, Filioussi K, Tsavaris N et al. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J. Clin. Oncol. 23, 8606-8612 (2005).
66. Prowell TM, Stearns V, Trock B. Lipophilic statins merit additional study for breast cancer chemoprevention. J. Clin. Oncol. 24(13), 2128-2129 (2006).
67. Satagopan JM, Offit K, Foulkes W et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol. Biomarkers Prev. 10, 467-473 (2001).
68. Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346(21), 1609-1615 (2002).
69. Meijers-Heijboer H, van Geel B, van Putten WLJ et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 345, 159-164 (2001).
70. King M-C, Wieand S, Hale K et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRC42: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial. JAMA 286, 2251-2256 (2001).